Literature DB >> 3740174

The ocular hypertensive effect of 0.25% fluorometholone in corticosteroid responders.

M Kass, J Cheetham, E Duzman, P J Burke.   

Abstract

Fourteen subjects known to be corticosteroid responders participated in a double-masked, randomized study comparing the ocular hypertensive effect of 0.25% fluorometholone suspension with that of 0.1% dexamethasone sodium phosphate. Subjects instilled one drop of fluorometholone in one eye and one drop of dexamethasone in the fellow eye four times daily for up to six weeks. Although both medications increased intraocular pressure, endpoint substitution analysis demonstrated that mean intraocular pressure increases from baseline in the eyes treated with fluorometholone were significantly lower than those in the eyes treated with dexamethasone at weeks 2, 4, and 6 (P less than or equal to .05). Also, mean maximum intraocular pressure was significantly lower in the eyes treated with fluorometholone than in the eyes treated with dexamethasone (P = .001). These results indicated that 0.25% fluorometholone is less likely to increase intraocular pressure in corticosteroid responders than 0.1% dexamethasone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740174     DOI: 10.1016/0002-9394(86)90137-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Beta1 and beta3 integrins cooperate to induce syndecan-4-containing cross-linked actin networks in human trabecular meshwork cells.

Authors:  Mark S Filla; Anne Woods; Paul L Kaufman; Donna M Peters
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

3.  Regulation of cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells by convergence of distinct beta1 and beta3 integrin pathways.

Authors:  Mark S Filla; Marie K Schwinn; Nader Sheibani; Paul L Kaufman; Donna M Peters
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-30       Impact factor: 4.799

Review 4.  The management of complicated glaucoma.

Authors:  C I Clement; Ivan Goldberg
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

5.  Risk Factors for the Development of Ocular Hypertension After Keratoplasty: A Systematic Review.

Authors:  Ilona Liesenborghs; Johannes S A G Schouten; Tos T J M Berendschot; Henny J M Beckers; Rudy M M A Nuijts; Nienke Visser; Carroll A B Webers
Journal:  Cornea       Date:  2020-03       Impact factor: 3.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.